help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krichevsky, A.
Right arrow Articles by Canfield, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krichevsky, A.
Right arrow Articles by Canfield, R.

Endocrinology, Vol 128, 1255-1264, Copyright © 1991 by Endocrine Society

ARTICLES

Development and characterization of a new, highly specific antibody to the human chorionic gonadotropin-beta fragment

A Krichevsky, S Birken, J O'Connor, K Bikel, J Schlatterer, C Yi, G Agosto and R Canfield
Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York 10032.

In addition to high concentrations of hCG, pregnancy urine contains even higher concentrations of a fragment of the hCG beta-subunit. This biologically inactive material complicates immunological measurement of hCG, since it cross-reacts with many polyclonal and monoclonal antibodies to the hCG beta-subunit that are employed for assays of hCG in urine. Although we and others have developed antibodies to this fragment, specific measurement of the fragment in the presence of free hCG beta has remained difficult due to intrinsic cross-reactivity of these antibodies with the intact hCG beta. Rather than attempt to increase specificity by assay optimization, we developed a new, highly specific monoclonal antibody, designated B210, which cross-reacts less than 0.1% with the free hCG beta-subunit in both liquid and solid phase immunoassay formats. We have used this new monoclonal antibody in immunoradiometric assays to measure specifically the hCG beta fragment in urine throughout pregnancy as well as in the sera of two individuals with cancers producing the hCG beta-subunit. We discovered that the hCG beta fragment can bind three monoclonal antibodies simultaneously, indicating that although the epitope for antibody B210 is a new determinant exposed on the hCG beta fragment and not on intact hCG or on free hCG beta-subunit, the hCG beta fragment retains at least two other hCG beta-related epitopes intact, i.e. those that bind monoclonal antibodies B108 and B201.


This article has been cited by other articles:


Home page
 Hum ReprodHome page
R. McChesney, A. J. Wilcox, J. F. O'Connor, C. R. Weinberg, D. D. Baird, J. P. Schlatterer, D.R. McConnaughey, S. Birken, and R. E. Canfield
Intact HCG, free HCG {beta} subunit and HCG {beta} core fragment: longitudinal patterns in urine during early pregnancy
Hum. Reprod., April 1, 2005; 20(4): 928 - 935.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. F. O'Connor, G. Kovalevskaya, S. Birken, and R. K. Iles
Interference of Luteinizing Hormone {beta}-Core Fragment in Urinary Gonadotropin Assays Dr. Iles responds:
Clin. Chem., December 1, 1999; 45(12): 2290 - 2292.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1991 by The Endocrine Society